We found that the activity of this signature gene set paralleled that of Smo mRNA expression in the patient cohort (ie, the calculated score was highest in the healthy-appearing control livers); among the NAFLD cohort, it declined progressively as the severity of liver fibrosis increased (Figure 12A). Here, SMO is linked to metabolic dysfunction-associated steatotic liver disease.